

NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 27 Jan 2020 (#3)

[Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

- NOT-AI-20-025 2020 NIAID Omnibus Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2020-1 Now Available for following NIAID Divisions: Division of Allergy, Immunology, and Transplantation (DAIT) and Division of Microbiology and Infectious Diseases (DMID). BAAs are general in nature, identifying areas of research interest, and shall only be used when meaningful proposals with varying technical/scientific approaches can be reasonably anticipated. Offerors may submit a proposal in response to one, or more, of the Research Areas:
 - 1. Development of Radiation/Nuclear Medical Countermeasures (MSMs). The objective of this Research Area is to advance the development of candidate MCMs to reduce mortality and/or major morbidities associated with exposure to radiation from a radiological or nuclear incident. Due date: 9 Apr 2020. Budget: NIAID estimates one or two cost-reimbursement, completion type contracts may be awarded for an average annual total cost (direct and indirect costs combined) of up to \$2 million. The total project period may not exceed 3 years.
 - 2. Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis (AFM) Associated with Enterovirus D68. **Due date:** 28 Feb 2020. **Budget:** NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to \$3 million. The total project period may not exceed five (5) years which includes stability studies.
 - 3. Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases. One objective of this Research Area is to develop vaccines to address antibiotic resistant gram-negative bacteria focusing on, but not limited to, *Burkholderia spp., Pseudomonas aeruginosa, Francisella tularensis, Yersinia pestis, and E. coli.* A second objective is to support development of vaccines for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (for example Eastern Equine Encephalitis) and bunyaviruses (for example Rift Valley Fever Virus). Due date: 9 Apr 2020. Budget: NIAID estimates that three or more awards for Research Area 003 & Research Area 004 may be issued for a total cost of up to total cost of up to \$11.5 million (direct and indirect costs combined). The total project period may not exceed five (5) years.
 - 4. Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases. The objective of this Research Area is the development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens. Category C includes Tuberculosis. This Research Area supports lead optimization, pre-clinical (IND enabling) and clinical trials that include Phase 1 and Phase 2 studies. Due date: 9 Apr 2020. Budget: NIAID estimates that three or more awards for Research Area 003 & Research Area 004 may be issued for a total cost of up to total cost of up to \$11.5 million (direct and indirect costs combined). The total project period may not exceed five (5) years.
 - 5. Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases. The objective of this Research Area is to advance the development of novel, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness. The capability to detect and distinguish among a required agent and multiple other pathogens common to a geographic region or population is strongly encouraged. Priority will be given to pathogens for which there are no U.S.-FDA approved/cleared/authorized diagnostics. Due date: 9 Apr 2020. Budget: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to \$2 million. The total project period may not exceed five (5) years.